Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving ...

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...